Overview: NGS Parkinson's Panel Sequencing TestIntroduction: The NGS Parkinson's Panel Sequencing Test sequences Parkinson's-related genes to diagnose Parkinson's disease, causing tremors or stiffness. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Parkinson's disease.
Other Names: Parkinson's NGS Assay, Parkinson's Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Parkinson's sequencing began in the 2000s with movement disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences Parkinson's-related genes to diagnose Parkinson's disease, guides treatment, and evaluates patients with tremors or stiffness.
Test Parameters: 1. Parkinson's Disease Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of tremors, stiffness, or Parkinson's symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document tremors, stiffness, bradykinesia, or family history of Parkinson's disease. Include current medications, especially levodopa.
Consent: Written consent required, detailing the tests purpose, Parkinson's disease implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze Parkinson's genes (e.g., LRRK2, SNCA). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Parkinson's diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm Parkinson's disease, guiding levodopa therapy or genetic counseling. Negative results may require DaTscan imaging.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: DaTscan, brain MRI, or neurological exam to confirm Parkinson's diagnosis.
Test Limitations: Not all Parkinson's cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Parkinson's Guidelines, 2023; Neurology, Postuma RB, 2022.
